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Background: According to recent guidelines, patients with coronary artery disease (CAD) should undergo
revascularization if significant myocardial ischemia is present. Both, cardiovascular magnetic resonance (CMR) and
fractional flow reserve (FFR) allow for a reliable ischemia assessment and in combination with anatomical information
provided by invasive coronary angiography (CXA), such a work-up sets the basis for a decision to revascularize or not.
The cost-effectiveness ratio of these two strategies is compared.
Methods: Strategy 1) CMR to assess ischemia followed by CXA in ischemia-positive patients (CMR + CXA), Strategy
2) CXA followed by FFR in angiographically positive stenoses (CXA + FFR). The costs, evaluated from the third party
payer perspective in Switzerland, Germany, the United Kingdom (UK), and the United States (US), included public
prices of the different outpatient procedures and costs induced by procedural complications and by diagnostic
errors. The effectiveness criterion was the correct identification of hemodynamically significant coronary lesion(s)
(= significant CAD) complemented by full anatomical information. Test performances were derived from the
published literature. Cost-effectiveness ratios for both strategies were compared for hypothetical cohorts with
different pretest likelihood of significant CAD.
Results: CMR + CXA and CXA + FFR were equally cost-effective at a pretest likelihood of CAD of 62% in Switzerland,
65% in Germany, 83% in the UK, and 82% in the US with costs of CHF 5′794, € 1′517, £ 2′680, and $ 2′179 per patient
correctly diagnosed. Below these thresholds, CMR + CXA showed lower costs per patient correctly diagnosed than
CXA + FFR.
Conclusions: The CMR + CXA strategy is more cost-effective than CXA + FFR below a CAD prevalence of 62%, 65%,
83%, and 82% for the Swiss, the German, the UK, and the US health care systems, respectively. These findings may help
to optimize resource utilization in the diagnosis of CAD.
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In many countries, cardiovascular diseases are the lead-
ing cause of morbidity and also of loss of quality of life.
In particular, coronary artery disease (CAD) constitutes
a major public health problem. In Europe the total costs
of CAD and stroke were estimated at 49 billion Euros in
the year 2008 [1] and for the United States these costs
were estimated as high as 156 billion dollars [2]. It is
well established that patients with no evidence of myo-
cardial ischemia have low cardiac events rates, even
when invasive coronary angiography (CXA) demon-
strates lesions of intermediate severity [3,4]. In addition,
patients without ischemia can be treated safely with
medical therapy [5,6] thereby reducing the total costs of
patient management [7]. On the other hand, randomized
trials e.g. in diabetic patients demonstrated a survival
benefit of patients with ischemia being treated by revas-
cularization versus medical treatment alone [8]. Accord-
ingly, recent guidelines recommend to revascularize
patients if a relevant burden of myocardial ischemia is
present (i.e. proximal vessel(s)) with a positive fractional
flow reserve (FFR) and/or >10% of myocardium ischemic
[9] or ≥2 ischemic segments in cardiovascular magnetic
resonance (CMR) perfusion examinations [10].
Nevertheless, neither vessel anatomy nor presence or
absence of ischemia is the factor that will exclusively de-
cide on revascularizations. Symptoms, co-morbidities
and other factors have to be taken into account before a
treatment decision is made. Thus, the current analysis
was undertaken to assess the cost-effectiveness to ac-
quire information (significant ischemia and full anatom-
ical information) relevant for decision making, but did
not include the costs for all information needed to man-
age patients with CAD. Also, we do not know whether a
large ischemia burden is directly related to adverse ef-
fects, whether it represents a marker of higher risk for
occlusion of a severe stenosis that causes ischemia, or
whether more severe ischaemia is simply a marker of
more extensive atherosclerosis and more vulnerable pla-
ques that go along with a worse outcome. Large trials
such as ISCHEMIA and others [11] will hopefully im-
prove our knowledge in a near future on how to treat is-
chemic patients. Despite this current lack of a detailed
understanding of the underlying mechanisms that link
ischemia to outcome, current guidelines recommend an
ischemia-based approach for decision making in patients
with CAD. Therefore, the aim of the current study was
to assess the cost-effectiveness of two diagnostic strat-
egies that are ischemia-based and provide both full ana-
tomical and functional evaluation of CAD, which are the
basis for a revascularization procedure.
A variety of new imaging techniques allow for such a
combined anatomical and functional assessment of
CAD, and as a result, the selection of the optimum testbecomes more and more challenging. The choice of car-
diovascular imaging techniques should consider both,
their clinical benefits for the patients as well as the costs
and cost-effectiveness compared to others. Invasive cor-
onary angiography (CXA) remains the reference for the
morphological assessment of CAD and it is often used
in daily practice as a first line test, e.g. in patients with a
positive treadmill test. While this strategy is not recom-
mended by current guidelines, the advent of the FFR
measurement to assess the hemodynamic significance of
coronary artery stenoses [12] may even increase the
attractivity to use invasive CXA as a first line test, as it
can be easily combined with FFR in case of intermediate
stenoses. Also, the FFR results were highly predictive for
patient outcome [13,14] and the combination of CXA
with FFR was more cost-effective than a CXA-only ap-
proach for the treatment of CAD [15]. Accordingly, re-
cent guidelines recommend using FFR to correctly
identify lesions that should undergo percutaneous cor-
onary interventions (PCI) [9]. However, the invasive na-
ture and radiation exposure of CXA and FFR limit their
usefulness in a screening process [16]. Considering the
fact that CXA is still extensively used in many industrial-
ized countries as an early step in the work-up of sus-
pected CAD [17,18], and further considering that FFR is
recommended in recent guidelines, the combination of
CXA + FFR was one diagnostic strategy to be assessed in
the current study with respect to its cost-effectiveness.
As an alternative to the FFR measurement, perfusion
CMR has emerged as a robust non-invasive technique
for the evaluation of myocardial ischemia [19-22]. Fur-
thermore, recent studies demonstrated the excellent
prognosis of patients with known or suspected CAD,
when perfusion-CMR was normal [23-25]. Accordingly,
in the present study, the cost-effectiveness of a com-
bination of CMR + CXA was compared with that of a
CXA + FFR strategy.
In the current economic context, the health care sys-
tems have to be economically sustainable while preserv-
ing high quality medical standards. Consequently, in the
following study we estimated the costs of the two different
strategies relative to their effectiveness to 1) correctly
diagnose the presence of relevant ischemia (= significant
CAD) and 2) to yield full anatomical information of the
coronary vasculature in case of ischemia. In particular, the
cost-effectiveness of the two strategies was compared
when applied to patient populations with varying CAD
pre-test probabilities. Strategy 1 consists of a CMR exam-
ination to assess ischemia followed by CXA in ischemia-
positive patients (CMR+CXA). This strategy yields
complete information on myocardial ischemia and cor-
onary anatomy. Strategy 2 consists of a CXA in all
patients followed by a FFR test in patients with inter-
mediate stenoses on CXA (CXA+ FFR). Finally, the cost-
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for the health care systems in Switzerland, Germany, the
United Kingdom, and the United States.
Methods
Using a mathematical model, we compared the cost-
effectiveness of 2 algorithms for diagnosing the presence of
hemodynamically significant coronary lesion(s) (= significant
CAD) for hypothetical patient cohorts characterized by dif-
ferent pretest likelihood of CAD (Pisch): 1) A perfusion CMR
to assess myocardial ischemia before referring positive
patients to CXA and 2) A CXA combined with an FFR in
patients with angiographically positive stenoses (see also
Figure 1).
Model characteristics
The model is based on Bayes’ theorem and consequently
assesses cost-effectiveness ratios of strategies in hypo-
thetical patient cohorts with different pretest likelihoods
of disease [26]. The mathematical model was initially
suggested by Paterson and co-workers [27] and was later
on applied by others [28-30]. The simulation approachFigure 1 Decision tree for CAD diagnosis including strategy 1 and strhas the advantage to allow the evaluation of diagnostic
algorithms for patients with different pretest likelihoods
of CAD regardless of currently accepted and applied
clinical strategies to detect CAD. In order to determine
the pretest likelihood of CAD in patients, the same testing
procedures would precede both strategies, i.e. CMR +
CXA and CXA + FFR, implying the same costs for both
strategies. Therefore, these “upstream” costs need not to be
considered in the model. Similarly, once a treatment deci-
sion is made, based on either diagnostic strategy the same
treatment costs will occur and therefore, these “down-
stream” costs were not considered either in the model. No
ethics approval was obtained for this study as it is based on
simulation model calculations and therefore no patients
data from our institution were required. Calculations were
performed with Microsoft Office Excel 2007 software.
Cost-effectiveness analysis
Definition of effectiveness
In the present study, the criterion of effectiveness is the abil-
ity to accurately identify those patients with one or more
hemodynamically significant coronary lesion(s) (=significantategy 2 used to design the model.
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on the coronary arteries. These patients with a relevant is-
chemia burden are the primary candidates for revasculariza-
tions according the most recent guidelines [10]. This
ischemia burden is defined in the newest guidelines as a
positive FFR of proximal coronary vessels [9,10] or by ≥2
segments with ischemia on perfusion-CMR [10]. The effect-
iveness criterion for strategy 1 is achieved by a positive
perfusion-CMR study (≥2 segments ischemic, see also
Table 1), which is complemented by a complete anatomical
information provided by a CXA examination in patients
positive for ischemia. For strategy 2, the effectiveness criter-
ion is achieved by the detection of a stenosis ≥50% in CXA
combined with an FFR ≤0.75 (= significant CAD). By as-
sumption, invasive CXA and FFR were the reference tests
with an assumed 100% diagnostic accuracy (Table 1). For
the calculation of hemodynamically significant lesions by
the CMR+CXA strategy, per-patient sensitivities (SnCMR =
0.88) and specificities (SpCMR = 0.90) were considered as de-
termined by Rieber et al. who compared ischemia on CMR
(i.e. ≥2 segment positive) versus FFR ≤0.75 as the reference
for ischemia [31]. Cost-effectiveness is defined as the costs
per effect which is calculated as the ratio between the total
costs and the number of patients correctly diagnosed as hav-
ing one or more hemodynamically significant coronary le-
sion(s) (true positive). Also, the costs of complications in
patients with a false negative diagnosis are included in the
cost-effectiveness ratio.
In this study, the objective of the analysis was to com-
pare cost-effectiveness ratios from the third party payer
perspective and not to assess the general impact of CAD
detection on the society welfare.Table 1 Test performance parameters used in the
effectiveness calculations
Abbreviation Description Parameter
value
Test to yield anatomical information (= detection of diameter
reduction ≥50%)
SnCXA Sensitivity of CXA 1
SpCXA Specificity of CXA 1
SnFFR Sensitivity of FFR 1
SpFFR Specificity of FFR 1
RCXA Rate of complications with invasive CXA 0.0005 [27]
Test to yield ischemia information (=detection of myocardial ischemia)
SnCMR Sensitivity of CMR (≥2 segments positive
vs FFR≤ 0.75)
0.88 [31]
SpCMR Specificity of CMR (≥2 segments positive
vs FFR≤ 0.75)
0.90 [31]
NDx Non diagnostic rate for CMR 0.05 [32]
RF Rate of complications per 10-year
follow-up period for patients with CAD
and false-negative tests
0.15 [27]When performing cost-effectiveness analysis, a wide
variety of factors and parameters related to the costs and
the performances of the tests have to be considered. The
model must be able to take into account the costs asso-
ciated with false-positive results (i.e. costs of unnecessary
diagnostic tests or treatments) as well as the costs associ-
ated with false negative results (i.e. costs of complications
because of inappropriate management of the disease). To
this end, data from the published literature on the perfor-
mances of tests (sensitivities, specificities and rate of non-
diagnostic examinations) and the complication rates were
used (Table 1).
To appropriately model strategy 2 (CXA + FFR), the
portion of patients with diameter stenoses ≥50% on
CXA having ischemia in FFR must be known. In other
words, the relationship between the probability of sten-
oses ≥50% on CXA (Psten) and the probability of having is-
chemia on FFR (Pisch) must be known. In order to assess
this relationship, we used published data from 5 recent ar-
ticles (see Additional file 1: Section A1 for details).Definition of costs and calculations of the costs per effect
The costs of a diagnostic strategy consist of first-line test
costs and subsequent costs. The first-line test costs are
the fees (Ft) for the CMR and CXA tests. Subsequent
costs were costs of additional tests (i.e. in case of non-
diagnostic CMR or unnecessary diagnostic tests in case
of false-positive results), costs of major complications in-
duced by the diagnostic procedure or resulting from
mis-diagnosis of a patient (e.g. as false negative patients
are at risk to have complications per 10-years follow-up
because of inappropriate management of the disease).
Due to the non-invasive nature of CMR and recent re-
sults showing that no severe complications occurred
in >17,000 CMR examinations (i.e. 7 mild reactions
in >7,200 stress CMR examinations) in the EuroCMR
registry [33] and in large multicenter trials [19], we as-
sumed that CMR is not associated with direct
procedure-related major complications. As an anaphyl-
actic shock is extremely rare and may occur after ad-
ministration of both MR- and CXA-related contrast
media, this complication was not considered in the ana-
lysis. We assumed that a potential complication associ-
ated with either a diagnostic CXA or an untreated
hemodynamically significant lesion (i.e. false negatives) is
a myocardial infarction (MI). Costs for this complication
(hereafter C) included medical costs associated with the
complications and accounted for a PCI, a hospital stay
of one week, and a rehabilitation period of 4 weeks. The
risk of developing malignancies induced by radiation ex-
posure was not incorporated into the model. Future
complications-related costs were discounted annually
at a rate of 3% [34].
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lated as the sum of direct costs and subsequent costs
multiplied by the respective number of patients. The
cost-effectiveness ratios were calculated for patient co-
horts with different pretest likelihoods ranging from 10%
to 100%.
The cost-effectiveness ratios were calculated as follows:
Cost effectiveness Ratio ¼ Direct cost þ subsequent costs
effectiveness
Calculations of the direct and subsequent costs and
the detailed equations are presented in the Additional
file 1: Section A2.
Evaluation of the costs in each country
The analyses were conducted from the third party payer
perspective in 4 countries. We used 2012 and 2013 costs
data in Swiss Francs (CHF) for Switzerland, in Euros (€)
for Germany, in Pounds (£) for the United Kingdom
(UK), and in American Dollars (US $) for the United
States. The Additional file 2 provides a brief description
on how the costs were derived for each country.
Sensitivity analysis
Due to the uncertainty of the data used and the numer-
ous assumptions (parameter values) made in these cal-
culations, a sensitivity analysis was performed to test the
robustness of the model. Thus, the model was re-run
with 1) changes in the costs of the tests and of the com-
plications, 2) changes in the rates of complications asso-
ciated with CXA, 3) changes in the accuracy of the CMRFigure 2 Example for the Swiss health care system: Proportion of pat
CMR + CXA and CXA + FFR strategies in relation to pre-test likelihoodtest, and 4) change in the threshold of FFR to detect is-
chemia (<0.75 vs <0.80; regarding the method used refer
to Additional file 1). In order to understand the impact
of each parameter in the model they were changed one
by one in the repeated calculations (for details, see the
figures related to the sensitivity analyses in the Results
section).
Results
Effect of the pretest likelihood of significant CAD on
effectiveness and on costs of the two strategies
Figure 2 shows the effect of the pretest likelihood of sig-
nificant CAD on effectiveness. The proportion of pa-
tients with CAD for whom a correct diagnosis is made
by the CMR-based strategy depends on its sensitivity,
specificity, and the rate of non-diagnostic CMR exami-
nations (Additional file 1: Section A2). As CXA and FFR
are assumed to be the reference with 100% accuracy, its
advantage compared to CMR increases as Pisch increases.
We derived that the difference between the 2 strategies
slightly decreases with an increase of the rate of patients
with non-diagnostic CMR tests (NDx). In the model, the
NDx patients after CMR are oriented to strategy 2 in
order to achieve 100% accuracy in these cross-over
patients.
Figure 3 shows the effect of pretest likelihood of sig-
nificant CAD on cost (example for the Swiss health
care system). The cost per patient tested increases
with increasing pre-test likelihood of significant CAD
for both strategies. The costs for CXA + FFR slightly
increase as the need for FFR increases with increasingients with suspected CAD correctly diagnosed (CAD Dx) by the
of significant CAD (Pisch.).
Figure 3 Costs per patient (Pt) tested in relation to the pre-test likelihood of significant CAD (=Pisch) for both strategies.
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strategy the costs increase steeply with increasing pre-
test likelihood of significant CAD, since patients posi-
tive for ischemia on CMR have to undergo CXA. The
two strategies are equally costly for a prevalence of
significant CAD of 0.87 (Figure 4). The value for such
a crossing point, within the range of Pisch (0 – 1.0) de-
pends on the relative costs of the tests and the accur-
acy of the CMR test (NDx and SnCMR and SpCMR)
(see formulas of costs).
When CXA is considered as inpatient test, the cost
per patient tested with strategy 1 (CMR + CXA) is lower
than the cost per patient tested with strategy 2 (CXA +
FFR) at any level of pre-test-likelihood of CAD.Comparison of the cost per effect and of cost-
effectiveness for the two strategies
Figure 4 shows the cost per effect, i.e. the cost per pa-
tient correctly diagnosed for significant CAD at various
levels of CAD prevalence in the 4 countries. We observe
that the cost per effect decreases hyperbolically for both
strategies as the pretest likelihood increases. The hyper-
bolic relationship between the prevalence of significant
CAD and the costs per patient correctly diagnosed shows
the high cost per effect in the patient population with low
prevalence of significant CAD (= low Pisch values). The
costs per effect at low values of Pisch are higher for strategy
2 (CX + FFR) than for strategy 1 (CMR +CXA).By assuming that all tests are outpatient tests, both
strategies are equally cost-effective at a pretest likelihood
of 62% in Switzerland, 65% in Germany, 83% in the UK,
and 82% in the United States with costs of CHF 5,794,
€ 1,517, £ 2,680, and $ 2,179 per patient correctly diag-
nosed, respectively. Below this threshold, CMR + CXA
shows lower costs per patient correctly diagnosed than
CXA + FFR. When the CXA test is performed as an in-
patient examination, the crossing point of the two
curves shifts towards the right to a prevalence of signifi-
cant CAD of 77% with costs of CHF 6,819 in
Switzerland, to 90% with costs of € 2′847 in Germany,
to 93% with costs of £ 4,633 in the UK, and to 94% with
costs of $ 3,849 in the US.Sensitivity analyses
Following a reduction of the sensitivity of the CMR
examination by 10% the crossing point shifted to the left
by 16, 20, 14, and 30 percentage points for the Swiss,
the German, the UK, and the US health care systems, re-
spectively. An increase of the CMR sensitivity by 10%
shifted the crossing point to the right by 15, 19, and 12
percentage points for the Swiss, the German, and the
UK health care systems, respectively. There is no cross-
ing point for Pisch <1 for the US health care system
(Figures 5, 6, 7 and 8), i.e. the costs of the CMR strategy
are lower than those of the CXA strategy in the US sys-
tem irrespectively of the pre-test likelihood of CAD.
Figure 4 Results for outpatient procedures performed in the 4 countries. Costs per effect (= cost-effectiveness) for both strategies in relation
to the prevalence of significant CAD (=Pisch).
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ence on the crossing point for all health care systems
assessed. This was also the case for the other variables
tested in the sensitivity analysis except the complications
rate. The sensitivity analysis shows that the rate for com-
plications caused by mis-diagnosed CAD, i.e. a lack of
detecting CAD, is associated with relevant cost-
effectiveness changes at least in the US system. If the
rate of complications in false-negative patients by CMR
is doubled the crossing point is shifted to the left by 10,
12, 6, and 23 percentage points in the Swiss, German,
UK, and US systems, respectively.
An increase of the FFR threshold to <0.80 did not sub-
stantially influence the cost-effectiveness results as
shown in (Figures 5, 6, 7 and 8). The crossing point
shifted to the left by 2 or 3 percentage points for the 4
health care systems.
Discussion
The main findings of this study can be summarized as
follows: 1) In all four health care systems analyzed, the
cost effectiveness ratio decreases hyperbolically for bothdiagnostic strategies with an increasing prevalence of
hemodynamically significant coronary lesions, i.e. with
an increasing prevalence of significant CAD. 2) The in-
crease in the cost-effectiveness for strategy 2, i.e. CXA +
FFR, with increasing prevalence of significant CAD is
more pronounced than that of the primarily non-
invasive CMR + CXA strategy, implying that there is a
threshold value of CAD prevalence where strategy 2 be-
comes more cost-effective than strategy 1. and 3) The
crossing point indicating an equal cost-effectiveness for
the 2 strategies varied for the 4 countries examined. In
Switzerland, strategy 1, i.e. CMR + CXA, is more cost-
effective than strategy 2 below a CAD prevalence of
62%. In the German, UK, and US health care systems, a
higher cost-effectiveness for CMR + CXA is given for a
CAD prevalence below 65%, 83%, and 82%, respectively.
CAD prevalence for optimum cost-effectiveness of various
strategies and current utilization of resources
Current clinical practice guidelines recommend proceed-
ing to PCI only, if relevant myocardial ischemia in symp-
tomatic patients is present [9,10]. Therefore, it appears
Figure 5 Sensitivity analysis: Switzerland.
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for ischemia assessment into models that assess the cost-
effectiveness of various strategies suggested for a CAD
work-up. Moreover, an FFR-guided PCI approach was
shown to be more cost-effective than a simple anatomy-Figure 6 Sensitivity analysis: Germany.guided, i.e. CXA-based PCI approach [7]. The current re-
sults show for all four health care systems assessed, that
the pre-test likelihood of CAD is a major factor that influ-
ences the cost-effectiveness of a CAD work-up. This is in
line with the fact that benefits from diagnostic tests
Figure 8 Sensitivity analysis: The United States.
Figure 7 Sensitivity analysis: The United Kingdom.
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the disease within the evaluated population [35]. Accord-
ing to the current analyses a non-invasive CMR-guided
approach is cost-effective for patients with an intermediate
pre-test likelihood of disease, which is in line with most
guidelines defining intermediate pre-test probabilities as
20-80%. Interestingly, in the US 62% of elective CXA ex-
aminations performed in a large sample of approximately
400,000 patients were found to be negative for CAD (sten-
oses <50% diameter reduction) [18], indicating that in the
US the pre-test probability of CAD in daily routine is as
low as ~38% which is substantially lower than the calcu-
lated threshold of 82%. Similarly, in the UK more than
58% of CXA examinations did not result in PCI or CABG
procedures [36] indicating that currently, the pre-test like-
lihood of significant CAD of patients referred for CXA of
42% is substantially lower than 83% calculated for the UK.
In the German health care system, the optimum pre-test
likelihood of CAD for a CMR-based strategy is below
65%. However, in 2008, only 43% of patients after CXA
were revascularized [17], indicating that an invasive ap-
proach was applied in a patient population with a rela-
tively low CAD prevalence of approximately 43%. Finally,
in Switzerland, the theoretical threshold for a directly in-
vasive strategy is at 62% CAD prevalence. The portion of
normal CXA studies ranged between 55% to 66% over the
last 3 years [37], which translates into an approximated
pre-test likelihood of significant CAD of 34-45% in
Switzerland, thus, again still lower than the prevalence for
a calculated optimal cost-effectiveness.
A cost analysis was recently performed based on the
data of the German sample of the European CMR regis-
try [38]. Cost savings of 50% were calculated between a
CMR strategy and an outpatient invasive CXA strategy
which is in line with the fact, that the pre-test probabil-
ity of CAD in this cohort was 27%, i.e. well below the
65% level. The cost savings for this cohort reported in
2012 would be even higher considering that for these
calculations costs for FFR were not yet included. Re-
cently, a cost-effectiveness analysis for UK was per-
formed based on the CE-MARC data [39]. For the
prevalence of CAD of 39% in CE-MARC [22], the diag-
nostic strategy based on CMR (preceded or not by a
treadmill test) followed by CXA in case of ischemia on
CMR was the most cost-effective strategy of all tested.
This finding is well in line with the current calculations
which suggest cost-effectiveness for the MR-based ap-
proach below a CAD prevalence of 83%. In this context,
it should be noted, that in the current study the thresh-
old in favor of a CMR-guided work-up compared cost-
effectiveness versus an outpatient CXA + FFR strategy. If
inpatient CXA is included into the model, the crossing
point shifts towards 77% for Switzerland, and is >90%
for Germany, the UK and the US. This indicates that theinpatient CXA + FFR procedures can only compete with
non-invasive CMR + CXA for very high rates of CAD
prevalence. This result is of even greater importance if
we note that in-patient CXA is performed in approxi-
mately 67% [40,41], 40% [36], and 88% [42], in the US,
the UK, and the German system, respectively.
Testing for ischemia by invasive vs non-invasive
techniques
For the current analyses, the FFR technique was as-
sumed to represent the gold standard. The assumption
appears justified in the light of a rapidly increasing num-
ber of studies confirming the high prognostic value of
FFR-guided PCI [5,6,12-14].
At a first glance, a SnCMR of 88% for ischemia detec-
tion (and of SnCMR = 80% in the sensitivity analysis) may
appear relatively high. However, similar and even higher
performances were reported with SnCMR/SpCMR of 82%/
94% [43] and SnCMR/SpCMR of 91%/94% [44]. Import-
antly, it should be taken into account that these SnCMR
for ischemia detection compare with an ischemia test,
i.e. FFR. When lower sensitivities of CMR for ischemia
detection are reported, they typically compare perfusion-
CMR with coronary anatomy. FFR is generally accepted
as a useful tool to guide treatment in CAD patients, as it
discriminates patients at risk for complications (FFR-
positive) versus those with minimal risk (FFR-negative).
In FFR-positive patients, complication rates (death and
non-fatal MI) were 3.2%-11.1%/y versus 0.7-7.3%/y in
FFR-negative patients [5,6]. In a recent registry-based
FFR study, MI in the FFR non-ischemia group was ~1%/y
vs ~1.9%/y in the ischemia group [12]. For perfusion
CMR, similar discriminative power was observed in ap-
proximately 1,700 patients of the EuroCMR registry,
with complications rates of 2.7%/y in CMR-positive pa-
tients, i.e. in patients with ischemia, versus 0.7%/y in
CMR-negative patients [24]. Thus, with this evidence of
a similar discriminative power for CMR and FFR, the
assumption of FFR being the gold standard, and thus,
classifying CMR results differing from FFR as incorrect,
might induce a bias towards an underestimation of the
cost-effectiveness of the CMR + CXA strategy.
Limitations
In the four countries, the unit costs for the cardiac ex-
aminations fed into the model may vary between differ-
ent geographical regions and therefore, the results are
representative for the entire health care systems under
study, but not for smaller geographical regions. In the
current model, no treatment costs were included. Cor-
rect absence of disease was not directly included in the
criterion of effectiveness but the effect was captured in-
directly through the costs of complications induced by
false negative results. The model does not take into
Moschetti et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:13 Page 11 of 13
http://jcmr-online.com/content/16/1/13account intangible costs associated with cardiac death.
This is because of the third-party-payer-perspective
study design. For the US context, we decided to use
costs for the material and a reimbursement of the phys-
ician to represent FFR costs similar to the approach used
by Fearon et al. [7] as the current US reimbursement
system does not consider costs for infrastructure nor
material. The sensitivity analyses showed a rather mod-
erate effect of prices for FFR on the cost-effectiveness
shifting the crossing point by ±6, ±8, ±8, and ±11 per-
cent points for the Swiss, the German, the UK, and the
US system, respectively.
Finally, the modeling approach used here implies that
some simplifications are built in and the decision process
to revascularize or not is reduced to the presence or ab-
sence of hemodynamically significant stenoses. It does
therefore not consider the clinical background of the pa-
tient, which is always important to guide treatment. Ac-
cordingly, the presented results might be helpful for
trials planning whereas the use of the presented model
with real CMR and FFR data acquired in ongoing trials
[11] would most likely yield more relevant results.
Conclusions
With a focus on the latest imaging techniques to detect
ischemia, this study shows to what extent the cost-
effectiveness of two strategies to diagnose hemodynamically
significant coronary lesions, i.e. significant CAD, depends
on the prevalence of the disease. The CMR+CXA strategy
is more cost-effective than CXA+ FFR below a CAD preva-
lence of 62%, 65%, 83%, and 82% for the Swiss, the
German, the UK, and the US health care systems, respect-
ively. These findings may help the decision-making with re-
gard to resource utilization.
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